文献速递糖尿病

2型糖尿病患者6年肺功能轨迹及其决定因素:Fremantle糖尿病研究II期

Pulmonary Function Trajectories Over 6 Years and Their Determinants in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.
PubMed 文献 · Diabetes Care · 2024-01-01

基于社区观察性Fremantle糖尿病研究II期(FDS2),对1074例2型糖尿病患者进行6年间每两年一次的FEV1%pred测量,采用基于组的轨迹模型识别出高、中、低、极低四组肺功能轨迹。极低组的主要糖尿病特异性显著预测因素为较高的HbA1c,死亡率从高组的6.7%递增至极低组的22.4%。作者认为测量2型糖尿病患者的肺功能有助于优化临床管理并改善预后,包括处理极低FEV1%pred者的血糖控制。

要点

  • 基于组的轨迹模型识别出4组FEV1%pred轨迹:高、中、低、极低。
  • 极低组的主要糖尿病特异性显著预测因素为较高的HbA1c。
  • 死亡率从高组的6.7%递增至极低组的22.4%。

核心结论

  • 在2型糖尿病中测量肺功能可能有助于优化临床管理并改善预后,包括处理极低FEV1%pred者的血糖控制。

研究设计与样本

  • 社区观察性Fremantle糖尿病研究II期(FDS2),纳入至少两次每两年一次FEV1%pred测量的2型糖尿病参与者,采用基于组的轨迹模型(GBTM)识别轨迹组,并用多项回归评估组别归属的独立相关因素。
  • 1482例潜在FDS2参与者中,1074例(72.5%;平均年龄65.2岁;45.5%女性;糖尿病病程中位数8.0年)纳入建模。

主要发现

  • 最佳拟合GBTM模型识别出4组FEV1%pred轨迹:高组19.5%(基线FEV1%pred 106.5±9.5%;斜率0%/年)、中组47.7%(FEV1%pred 87.3±8.7%;斜率-0.32%/年)、低组25.0%(基线FEV1%pred 68.9±9.8%;斜率-0.72%/年)、极低组7.9%(基线FEV1%pred 48.8±9.6%;斜率-0.68%/年)。
  • 与高组相比,其他组具有与一般人群肺功能下降相关的不可改变和可改变风险因素(包括种族、婚姻状况、吸烟、肥胖、冠心病和慢性呼吸系统疾病)。
  • 极低组的主要糖尿病特异性显著预测因素为较高的HbA1c。
  • 死亡率从高组的6.7%递增至极低组的22.4%。

临床怎么用

  • 作者认为,在2型糖尿病中测量肺功能可能有助于优化临床管理并改善预后,包括处理极低FEV1%pred者的血糖控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether there are clusters of people with type 2 diabetes with distinct temporal profiles of lung function changes and characteristics. RESEARCH DESIGN AND METHODS: Group-based trajectory modeling (GBTM) identified groups of participants with type 2 diabetes from the community-based observational Fremantle Diabetes Study Phase II (FDS2) who had at least two biennial measurements of forced expiratory volume in 1 s as a percentage of predicted (FEV1%pred) over 6 years. Independent associates of group membership were assessed using multinomial regression. RESULTS: Of 1,482 potential FDS2 participants, 1,074 (72.5%; mean age, 65.2 years; 45.5% female; median diabetes duration, 8.0 years) were included in the modeling. The best fitting GBTM model identified four groups categorized by FEV1%pred trajectory: high (19.5%; baseline FEV1%pred, 106.5 ± 9.5%; slope 0%/year), medium (47.7%; FEV1%pred, 87.3 ± 8.7%; slope, -0.32%/year), low (25.0%; baseline FEV1%pred, 68.9 ± 9.8%; slope, -0.72%/year), and very low (7.9%; baseline FEV1%pred, 48.8 ± 9.6%; slope, -0.68%/year). Compared with the high group, the other groups were characterized by nonmodifiable and modifiable risk factors associated with lung function decline in the general population (including ethnicity, marital status, smoking, obesity, coronary heart disease, and chronic respiratory disease). The main, diabetes-specific, significant predictor of group membership was a higher HbA1c in the very low group. There was a graded increase in mortality from 6.7% in the high group to 22.4% in the very low group. CONCLUSIONS: Measurement of lung function in type 2 diabetes could help optimize clinical management and improve prognosis, including addressing glycemic control in those with a very low FEV1%pred.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Davis TME, Drinkwater JJ, Davis WA, et al. Pulmonary Function Trajectories Over 6 Years and Their Determinants in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care. 2024. PMID: 38211617. doi:10.2337/dc23-1726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。